Dear Colleagues,

Chemotherapy, radiotherapy, immunotherapy and clinical surgery, although used today to eradicate cancer cells, are highly nonselective and commonly result in unexpected sides effects, leading frequently to the death of normal cells. Therefore, advanced research is underway to develop new anticancer methods and techniques, which are no longer limited to new chemotherapeutic agents. One of the newest and most promising tools in the treatment of cancer which has been extensively investigated is cold atmospheric pressure plasma (CAPP)-based protocols, often associated with the simultaneous action of the chemotherapeutic drugs, nanoparticles or nanomaterials that carry these chemotherapeutics. CAPP generates reactive oxygen and nitrogen species, UV radiation as well as various charged and uncharged reactive particles and species that tend to change biological cells’ surfaces by inducing oxidative stress. As a result, this interference with the cell microenvironment is responsible for certain desired changes in gene activity and markers of expression of cancer cells, leading to the efficient inhibition of their growth and a selective reduction in their number by apoptosis or other death mechanisms. A synergistic effect of CAPP treatment on cancer cells can be achieved by including nanomaterials. In this case, CAPP helps in increasing the cell membrane’s permeability, which allows the more efficient invasion of nanoparticles or nanomaterial-based drug delivery carriers towards selected sites affected by the cancer and lesions. Moreover, the simultaneous action of CAPP and nanomaterials can help in tissue regeneration by stimulating normal cell proliferation as well as inactivating a broad spectrum of pathogenic microorganisms, including, particularly, those which are multidrug-resistant.

The current Special Issue seeks contributions from scientists and researchers dealing with new applications of CAPP and the development of appropriate plasma devices to treat cancer and alleviate its effects in the body. In particular, it is focused on the effects of CAPP on the microenvironment of cancer cells, the induction of their programmed death, as well as the positive effect on normal cells. Scientific works devoted to the synergistic antitumor activity of CAPP and nanomaterials are particularly welcome.

Potential topics include, but are not limited to, the following:

• Liquid-mediated and surface-mediated effects of CAPP on cancer and normal cells, including cell proliferation, apoptosis, migration and permeability;
• In vitro and in vivo studies of selective CAPP treatment of various tumors;
• Combination of CAPP and nanomaterials for noninvasive cancer treatment;
• Application of CAPP and nanomaterials in tumor therapy and tissue regeneration.

Prof. Dr. Pawel Pohl
Dr. Piotr Jamroz
Dr. Anna Dzimitrowicz
Dr. Aleksandra Bielawska-Pohl
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Non-thermal plasma atmospheric plasma
• Dielectric barrier discharge
• Atmospheric pressure plasma jet
• Plasma-liquid interactions
• Plasma medicine
• Cancer and tumor treatment
• Anticancer therapy
• Nanomaterials